Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access to Rovalpituzumab Tesirine

Trial Profile

Expanded Access to Rovalpituzumab Tesirine

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 23 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top